FDAnews Drug Daily Bulletin

ALLERGAN'S CHAIRMAN AND CHIEF EXECUTIVE OFFICER ADOPTS RULE 10B5-1 STOCK TRADING PLAN

April 17, 2006
A A

Allergan, Inc. today announced that David E.I. Pyott, Chairman of the Board and Chief Executive Officer, has entered into a Rule 10b5-1 plan to effect the orderly exercise of certain employee stock options and the sale of underlying shares over an approximately two and a half year period ending in August of 2008. The stock options subject to the plan — which represent less than 25% of Mr. Pyott's currently granted employee stock options — are from grants made in 1997 through 1999, as well as certain premium-priced stock options that expire in 2007.
Business Wire